Clinical trials: Influenza Human
Influenza, Human
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza…
- Trial name
- NCT05540522
- Testing
- Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine
- Where
- 321 sites in United States, Argentina and 4 more
- Volunteers
- 45,789 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
The purpose of this study is to demonstrate the effectiveness (seroprotection and seroconversion as measured by the hemagglutination inhibition [HI] assay) of an investigational Vero cell-derived, trivalent, seasonal influenza…
- Trial name
- NCT00782431
- Testing
- Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
- Where
- 30 sites in United States
- Volunteers
- 3,208 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
The study primarily aims to evaluate immunogenicity and safety of influenza vaccines (cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free…
- Trial name
- NCT00579345
- Testing
- Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a
- Where
- 5 sites in Poland
- Volunteers
- 1,522 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza, Human, SARS-CoV-2 Infection
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the…
- Conditions
- Influenza, Human, SARS-CoV-2 Infection, COVID-19
- Trial name
- NCT06237049
- Testing
- BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV
- Where
- 30 sites in United States
- Volunteers
- 644 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered…
- Trial name
- NCT05526716
- Testing
- V116, QIV
- Where
- 56 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Influenza
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
To evaluate the safety of a single intramuscular (IM) injection of trivalent adjuvanted influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody response to each influenza vaccine antigen, as measured…
- Trial name
- NCT01651104
- Testing
- Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00835926
- Testing
- Influenza virus vaccine
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season
- Trial name
- FluMist (NCT02473510)
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains
The study is to assess whether the influenza vaccine Inflexal V for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01631110
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Avian Influenza, H1N1 Influenza
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and…
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Trial name
- NCT02921997
- Testing
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern Hemisphere
A study to assess whether the Northern Hemisphere 2008/2009 season influenza vaccine Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines
- Trial name
- NCT01303510
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza Infection
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)
This is a phase 2a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of molnupiravir (MK-4482) in healthy participants inoculated with experimental influenza virus.
- Trial name
- NCT05818124
- Testing
- Molnupiravir, Oseltamivir, Influenza A Virus
- Where
- United Kingdom
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Influenza, Respiratory Viral Infection
Test-and-treat for Influenza in Homeless Shelters
This study is a stepped-wedge cluster-randomized trial of on-site rapid testing and treatment for influenza in homeless shelters within the Seattle area to determine whether this strategy reduced the incidence of influenza in the…
- Trial name
- NCT04141917
- Testing
- Point-of-care molecular testing and treatment of influenza
- Where
- 9 sites in United States
- Volunteers
- 1,618 people
- Sponsor
- University of Washington
2009 H1N1 Influenza Virus
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older.
- Trial name
- NCT01055184
- Testing
- 2009 H1N1 Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.
To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).
- Trial name
- NCT00390884
- Testing
- Influenza Virus Vaccine, Fluzone®
- Where
- 5 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in adults aged 18 to 60 years.
- Trial name
- NCT00989287
- Testing
- GSK2340272A, GSK2340269A
- Where
- Belgium
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthmatic
Influenza Vaccine Feasibility Study in Children With Persistent Asthma
This study is designed to note whether a larger safety study using quadrivalent live attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine (IIV4)(FLUARIX®), would be feasible in children with…
- Trial name
- NCT02967393
- Testing
- ccIIV4, IIV4
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Acute Respiratory Viral Infections, Influenza
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs.
- Trial name
- NCT03455491
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 11 sites in Russia
- Volunteers
- 120 people
- Sponsor
- PHARMENTERPRISES LLC
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
- Trial name
- NCT00735475
- Testing
- CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
- Where
- 13 sites in United States
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of…
- Trial name
- NCT00976027
- Testing
- Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 9,172 people, healthy volunteers welcome
- Sponsor
- Sanofi